
    
      Inclusion criteria were CHB patients with resistance to more than two classes of
      nucleos(t)ide analogues (NA) and hepatitis B virus (HBV) DNA level â‰¥200 IU/mL.

      Patients will receive either TDF-base combination therapy or TDF monotherapy. The primary end
      point is virologic response (VR) defined by an undetectable HBV DNA (<20 IU/mL) at month 36.
    
  